1
Home
Companies

Biofrontera

#10421

Rank

$12.35M

Marketcap

US United States

Country

Biofrontera
Leadership team

Dr. Hermann Lubbert Ph.D. (Exec. Chairman & Pres)

Ms. Erica L. Monaco CPA (CEO, COO, Treasurer & Sec.)

Mr. Eugene Fredrick Leffler III (Chief Financial Officer)

Products/ Services
Biopharma, Health Care, Pharmaceutical
Number of Employees
50 - 100
Headquarters
Leverkusen, Nordrhein-Westfalen, Germany
Established
1997
Company Registration
SEC CIK number: 0001858685
Revenue
20M - 100M
Traded as
BFRI
URL
https://www.biofrontera-us.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.
History

Biofrontera was founded in 1997 as a thematically directed research and development company for pharmaceuticals and cosmetics. Biofrontera has developed a broad portfolio dermatology products, including photodynamic therapy. In 2004, Biofrontera established its US subsidiary and in 2006, the company went public on the Frankfurt Stock Exchange with an initial public offering. In 2015, Biofrontera won the Frost & Sullivan Global Company of the Year – Dermatology award.

Mission
Biofrontera strives to make a positive impact through providing innovative, safe, and effective therapeutics and treatments for dermatology and skin care. In addition, Biofrontera is committed to research and development in order to expand its portfolio of products and services that improve the quality of life for patients.
Vision
Biofrontera has a vision to become the leading provider of innovative dermatological treatments and products that improve the quality of life of people with skin conditions.
Key Team

Mr. Daniel Hakansson J.D. (Gen. Counsel & Head of Compliance)

Mr. Mark Baldyga (Head of Sales & Marketing)

Mr. Jeff Holm (Head of Professional Relations & Commercial Devel.)

Ms. Erica F. Gates CPA, M.B.A. (Sr. Director of Fin. & Principal Accounting Officer)

Ms. Alycia Torres (VP of Admin.)

Recognition and Awards
In 2015, Biofrontera won the Frost & Sullivan Global Company of the Year – Dermatology award, and has also been recognized by the German business publication Manager Magazin as one of the Top Innovators of the Year. In 2019, Biofrontera was awarded the German Dermatology Prize.
References

https://de.wikipedia.org/wiki/Biofrontera

https://in.investing.com/equities/biofrontera

https://finance.yahoo.com/quote/BFRI/profile?p=BFRI

https://www.crunchbase.com/organization/biofrontera

https://companiesmarketcap.com/

https://www.biofrontera-us.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Biofrontera
Leadership team

Dr. Hermann Lubbert Ph.D. (Exec. Chairman & Pres)

Ms. Erica L. Monaco CPA (CEO, COO, Treasurer & Sec.)

Mr. Eugene Fredrick Leffler III (Chief Financial Officer)

Products/ Services
Biopharma, Health Care, Pharmaceutical
Number of Employees
50 - 100
Headquarters
Leverkusen, Nordrhein-Westfalen, Germany
Established
1997
Company Registration
SEC CIK number: 0001858685
Revenue
20M - 100M
Traded as
BFRI
URL
https://www.biofrontera-us.com